In one of the year’s most highly anticipated decisions, the FDA on Tuesday approved Eli Lilly and Company's donanemab, an anti-amyloid antibody designed as the third drug to modify the course of Alzheimer’s disease. https://hubs.li/Q02FdtkW0 #pharma #biospace
Exciting news from Eli Lilly & Company! The FDA's approval of donanemab marks a significant advance in Alzheimer's disease treatment.
Despite an uncertain legislative path to becoming law, the BIOSECURE Act has already impacted the biopharma industry’s confidence in Chinese service providers and prompted efforts to diversify manufacturing partners. https://hubs.li/Q02FfWYy0
Biopharma Layoff Tracker 2024: Apollomics, CureVac, Takeda and More Cut Staff https://hubs.li/Q02FfXbg0
Taysha Gene Therapies looks to move past its pipeline culls and staff reductions by moving its lead asset into a possible billion-dollar market. https://hubs.li/Q02Ff_nC0
President Joe Biden and Sen. Bernie Sanders in a Tuesday op-ed in USA Today called on Novo Nordisk and Eli Lilly to “stop ripping off Americans” with “unconscionably high prices” for their GLP-1 medicines. https://hubs.li/Q02Ff_mJ0
As congressional pressure increases on WuXi AppTec and other China-based companies over alleged ties to the Chinese government, India’s contract development and manufacturing organization sector could benefit. https://hubs.li/Q02FfW550
Two CRLs from the FDA last week cited concerns with third-party manufacturers, while Indian CDMOs may make a bid for U.S. business if there is a decoupling from Chinese companies under the BIOSECURE Act. https://hubs.li/Q02Ff_tc0
Johnson & Johnson and Legend Biotech's Carvykti cell therapy significantly improved survival in patients with multiple myeloma when used in the second-line setting, the companies announced on Tuesday. https://hubs.li/Q02FdD7z0 #pharma #biospace
GSK on Wednesday restructured its contract with CureVac to gain access to the biotech’s influenza and COVID-19 programs for $430 million upfront and up to $1.13 billion in future payments. https://hubs.li/Q02Fdyvz0 #pharma #biospace
Eli Lilly and Company is expanding its radiopharmaceutical portfolio with a $140 million upfront payment to Radionetics Oncology and the exclusive future right to acquire the biotech for $1 billion. https://hubs.li/Q02F2nlJ0 #pharma #biospace
Financial Author, Publisher, Educator, Analyst, Professional Investor
3dWhile these first two drug approvals are still sub-optimal, to have anything at all is such a big deal. There was no progress at all for many years or even decades and it was so devastating for families. Bit by bit we're getting there. " If you can't fly then run. If you can't run then walk, if you can't walk then crawl.... But just keep moving in the right direction." -MLK